📷 Image: Wikimedia Commons / Alok Singh Oberoi
Entertainment
FDA Notices to Shah Rukh Khan, Ajay Devgn, Tiger Shroff Explained by Tukaram Mundhe
✍️ Outlook India
🗓 27 Aug 2026, 07:17 AM
👁 2
Food safety regulator has issued notices to leading Bollywood actors Shah Rukh Khan, Ajay Devgn and Tiger Shroff, with industry analyst Tukaram Mundhe outlining the reasons behind the alerts.
The Food and Drug Administration (FDA) has sent formal notices to three high‑profile Bollywood stars – Shah Rukh Khan, Ajay Devgn and Tiger Shroff – over alleged breaches of advertising and promotional guidelines. The notices, issued this week, cite possible non‑compliance with the Food Safety and Standards Act concerning health‑related product endorsements.
Industry commentator Tukaram Mundhe, speaking to Outlook India, clarified that the regulatory action stems from the actors' involvement in campaigns that may have made unverified health claims. He noted that the FDA typically requires clear evidence and appropriate disclosures before celebrities can promote such products.
Mundhe added that the actors are expected to respond within the stipulated timeframe, either by providing the necessary documentation or by withdrawing the contested advertisements. He emphasized that the process is routine and aims to protect consumers from misleading information.
The three actors have not publicly commented on the notices as of now. The FDA has indicated that it will monitor compliance closely and may take further action if the concerns are not addressed.
Industry commentator Tukaram Mundhe, speaking to Outlook India, clarified that the regulatory action stems from the actors' involvement in campaigns that may have made unverified health claims. He noted that the FDA typically requires clear evidence and appropriate disclosures before celebrities can promote such products.
Mundhe added that the actors are expected to respond within the stipulated timeframe, either by providing the necessary documentation or by withdrawing the contested advertisements. He emphasized that the process is routine and aims to protect consumers from misleading information.
The three actors have not publicly commented on the notices as of now. The FDA has indicated that it will monitor compliance closely and may take further action if the concerns are not addressed.